Merck signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion.

Now, its closest competitors include Regeneron's odronextamab, Genmab/AbbVie's epcoritamab, and Roche's mosunetuzumab and glofitamab. Turning to the CD28 programme, the company acknowledged this ...